Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
AEON Biopharma, Inc. (AEON) had Return on Tangible Equity of 71.28% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-39.22M |
|
-- |
|
-- |
|
$12.80M |
|
$-12.80M |
|
$-26.42M |
|
$-39.22M |
|
$-39.22M |
|
$-39.22M |
|
$-39.22M |
|
$-39.22M |
|
$-39.22M |
|
$-12.80M |
|
$-12.72M |
|
9.92M |
|
9.92M |
|
$-3.95 |
|
$-3.95 |
|
| Balance Sheet Financials | |
$3.40M |
|
$0.16M |
|
$2.16M |
|
$5.56M |
|
$6.90M |
|
$34.60M |
|
$53.69M |
|
$60.59M |
|
$-55.03M |
|
$-55.03M |
|
$-55.03M |
|
12.11M |
|
| Cash Flow Statement Financials | |
$-17.31M |
|
$-0.00M |
|
$20.30M |
|
$0.01M |
|
$3.01M |
|
$2.99M |
|
$5.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.49 |
|
-- |
|
-- |
|
-1.69 |
|
-0.63 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.31M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
71.28% |
|
|
Return on Tangible Equity |
71.28% |
-705.43% |
|
192.01% |
|
$-4.55 |
|
$-1.74 |
|
$-1.74 |
|